December 16, 2024 – INCATE (the INCubator for Antibacterial Therapies in Europe), is delighted to announce the extension of its strategic partnership with the Kineticos AMR Accelerator Fund I (KAMRA I). Building on the successful collaboration initiated in 2023, this renewed partnership underscores a shared commitment to supporting early-stage innovations in the fight against antimicrobial resistance (AMR).

Through this partnership, Kineticos will continue to provide R&D and strategic support to promising early-stage innovations within the INCATE ventures, helping accelerate the development of next-generation antimicrobial medicines.

“The extension of our partnership with Kineticos represents a significant milestone in our mission to address the urgent need for innovative antimicrobial therapies,” said Iringó Demeter, member of the INCATE management team. “Their expertise and investment capabilities are fundamental in supporting the technologies our innovators are developing.”

“Continuing our partnership with INCATE reflects our shared vision of supporting breakthrough innovations in the antimicrobial space,” said Richard Snyder, Ph.D., KAMRA I Venture Partner. “We are excited to build on the momentum we’ve achieved together and look forward to backing new, high-potential projects and companies that have the potential to make a global impact.”

By extending its alliance with Kineticos, INCATE will strengthen its ability to provide guidance and increase access to funding. Additionally, Kineticos is expected to keep on playing an active role in helping select ventures with compelling business cases to attract further investment in the AMR field.

The INCATE support model has demonstrated significant value for early-stage ventures and will continue to grow, reaching new regions and fomenting collaborations with both existing and new partners. We are excited to support more innovators in their efforts to combat drug-resistant bacterial infections.

About Kineticos

Kineticos Life Sciences (Kineticos) envisions a world without antimicrobial resistance, cancer, and rare and neurodegenerative diseases. We are entrepreneurs helping entrepreneurs build companies to improve patient outcomes. Kineticos leverages our expertise, network, ecosystem, and capital to provide the most relevant insights and recommendations for our portfolio companies, building value every step of the way. Kineticos began investing in 2019 and through its investment vehicles has invested more than $75M across 13 companies, as of September 30, 2024.

Contact: investorrelations@kineticos.com
www.kineticos.com
LinkedIn: @Kineticos

About INCATE 

INCATE is a not-for-profit partnership which brings together translational and basic research, industry, experienced entrepreneurs, and investors from across Europe and beyond. The German Center for Infection Research (DZIF), the Leibniz:HKI (part of Leibniz Association) in Germany, the Swiss National Centre of Competence in Research AntiResist, the University of Basel are the academic founding members of INCATE with the University of Basel acting as the host. Together with the four industry partners Boehringer Ingelheim, Roche, Shionogi and MSD as well as other organizations, funders and investors, INCATE wants to ensure that the pipeline of new antibiotics and technology platforms is growing and strengthened.

For more information please contact:

helena.costa.pereira@incate.net or +49 176 46172549
www.incate.net
Linkedin: @INCATE
X (former Twitter): @INCATEurope
YouTube: @INCATEurope